Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:DSGN NASDAQ:GALT NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.36-2.1%$7.62$6.13▼$17.43$655.86M1.461.40 million shs901,608 shsDSGNDesign Therapeutics$10.65-1.0%$12.30$3.33▼$17.25$665.17M1.631.27 million shs779,486 shsGALTGalectin Therapeutics$2.33-2.1%$2.40$1.28▼$7.13$153.45M0.47330,895 shs215,793 shsTLRYTilray Brands$4.94-4.8%$6.07$3.51▼$23.20$575.75M1.883.07 million shs7.82 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix0.00%-0.95%+5.56%+29.41%-32.47%DSGNDesign Therapeutics0.00%+1.62%-24.47%+5.97%+159.76%GALTGalectin Therapeutics0.00%-7.54%+10.43%-24.84%+82.03%TLRYTilray Brands0.00%-10.34%-12.72%-31.48%+20.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.36-2.1%$7.62$6.13▼$17.43$655.86M1.461.40 million shs901,608 shsDSGNDesign Therapeutics$10.65-1.0%$12.30$3.33▼$17.25$665.17M1.631.27 million shs779,486 shsGALTGalectin Therapeutics$2.33-2.1%$2.40$1.28▼$7.13$153.45M0.47330,895 shs215,793 shsTLRYTilray Brands$4.94-4.8%$6.07$3.51▼$23.20$575.75M1.883.07 million shs7.82 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix0.00%-0.95%+5.56%+29.41%-32.47%DSGNDesign Therapeutics0.00%+1.62%-24.47%+5.97%+159.76%GALTGalectin Therapeutics0.00%-7.54%+10.43%-24.84%+82.03%TLRYTilray Brands0.00%-10.34%-12.72%-31.48%+20.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.75Moderate Buy$15.0079.43% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5054.93% UpsideGALTGalectin Therapeutics 2.00Hold$11.00372.10% UpsideTLRYTilray Brands 2.25Hold$11.50132.79% UpsideCurrent Analyst Ratings BreakdownLatest GALT, CRMD, DSGN, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026DSGNDesign Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026DSGNDesign Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.004/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026DSGNDesign Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.004/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.004/28/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.00(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$311.71M2.10$2.04 per share4.09$5.14 per share1.63DSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/ATLRYTilray Brands$821.31M0.70$1.44 per share3.42$14.04 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix$163.05M$2.133.9246.44N/A45.25%45.57%24.76%8/6/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest GALT, CRMD, DSGN, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/A4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 million3/31/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/9/2026Q4 2025DSGNDesign Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedix0.332.972.74DSGNDesign TherapeuticsN/A22.2822.28GALTGalectin TherapeuticsN/A2.152.15TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%DSGNDesign Therapeutics56.64%GALTGalectin Therapeutics11.68%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.50%DSGNDesign Therapeutics17.10%GALTGalectin Therapeutics52.60%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.45 million75.71 millionOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableGALT, CRMD, DSGN, and TLRY HeadlinesRecent News About These CompaniesHow The Tilray Brands (TLRY) Story Is Shifting With Rescheduling Hopes And Profit ConcernsJune 6 at 12:28 AM | finance.yahoo.comThe Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching: 2 Marijuana Stocks to Buy NowJune 6 at 12:15 AM | fool.comCannabis Stocks To Keep An Eye On - June 3rdJune 6 at 4:05 AM | americanbankingnews.comWhy Tilray Diversified Strategy Is Drawing Attention?June 6 at 3:54 AM | kalkinemedia.comKTLRY Stock Back Into The Limelight – A Look At The Key Developments That Sparked Investor OptimismJune 5 at 12:07 PM | stocktwits.comSTop Cannabis Stocks To Add to Your Watchlist - June 2ndJune 5 at 4:44 AM | americanbankingnews.comBreckenridge Distillery Introduces Breckenridge Rye Whiskey, A Bold New Expression from the World’s Highest DistilleryJune 4 at 7:43 AM | finance.yahoo.comBreckenridge Distillery Introduces Breckenridge Rye Whiskey, A Bold New Expression from the World's Highest DistilleryJune 4 at 7:00 AM | globenewswire.comIs This Why Tilray Brands Inc. (TLRY) is one of the Best Sin Stocks to Buy?June 3, 2026 | finance.yahoo.com3 Canadian Marijuana Stocks That Could Help You Make MoneyJune 3, 2026 | marijuanastocks.comMSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3, 2026 | finance.yahoo.comSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3, 2026 | financialpost.comFSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3, 2026 | globenewswire.comTilray Brands, Inc. (TLRY) Stock Slides as Market Rises: Facts to Know Before You TradeJune 2, 2026 | finance.yahoo.comTilray Brands, Inc. (TLRY) Stock Slides as Market Rises: Facts to Know Before You TradeJune 2, 2026 | zacks.comTop Cannabis Stocks To Add to Your Watchlist - May 31stJune 1, 2026 | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Trading Down 2.5% - Should You Sell?May 31, 2026 | americanbankingnews.comPromising Cannabis Stocks To Consider - May 28thMay 31, 2026 | americanbankingnews.comCuraleaf Prepares for US Exchange Uplisting: Time to Invest?May 29, 2026 | zacks.comTilray Brands (NASDAQ:TLRY) Stock Price Up 1.8% - Here's WhyMay 28, 2026 | marketbeat.comTop Canadian Marijuana Stocks for Your Watchlist Before June 2026May 28, 2026 | marijuanastocks.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, CRMD, DSGN, and TLRY Company DescriptionsCorMedix NASDAQ:CRMD$8.36 -0.18 (-2.11%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$8.32 -0.04 (-0.44%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Design Therapeutics NASDAQ:DSGN$10.65 -0.11 (-1.02%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$11.32 +0.67 (+6.30%) As of 06/5/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Galectin Therapeutics NASDAQ:GALT$2.33 -0.05 (-2.10%) As of 06/5/2026 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Tilray Brands NASDAQ:TLRY$4.94 -0.25 (-4.82%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.92 -0.02 (-0.30%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
